XML 43 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Fair Value Measurements - Summary of Derivative Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3) (Details)
$ in Thousands
6 Months Ended
Jun. 30, 2022
USD ($)
Celularity  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance $ 87,657
Ending balance 61,559
Restricted Shares | Celularity  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Change in fair value measurement (26,098)
Derivative Liabilities  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance 35,700
Change in fair value measurement (35,200)
Ending balance 500
ACEA Therapeutics, Inc  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Beginning balance 124,746
Change in fair value measurement (66,400)
Ending balance $ 58,346